Aufero Medical is revolutionizing cardiac ablation with TruContact, a robotic tool that enhances catheter stability to better treat atrial fibrillation and other heart rhythm disorders. Unstable catheters, common in half of all procedures, dramatically cut success rates. TruContact leverages robotics and machine learning to ensure a stable catheter, producing high-quality ablations, and empowering physicians of all experience levels. Partnered with leading EP market players, TruContact is integrated with popular catheter systems to reach a global market. Backed by top executives and KOLs, Aufero has raised over $1M+, generated strong preclinical data, and secured strategic partners.

The 2025 HRX Pitch Competition offers a unique opportunity to showcase TruContact and gain visibility among industry leaders, investors, and clinicians to accelerate our mission to transform cardiac care.

Skribe Medical is developing a wearable patch for early detection of cardiotoxicity during cancer therapy. We’re protecting the long-term heart health of cancer survivors and making it easy for oncologists meet required cardiac screening guidelines. We’ve built a novel wireless power and communication technology that allows our patch to be tiny, lightweight, and battery-free.

We are thrilled for the chance to share our ideas with the thought leaders and innovators at HRX, and to bring awareness to the importance of cardiovascular health for cancer patients and survivors

Acorai is a Swedish MedTech company developing a non-invasive monitoring device for heart failure management. Using a patented multi-sensor system powered by machine learning, Acorai estimates cardiac and pulmonary pressures – key indicators for guiding treatment – without the need for invasive procedures. Backed by clinical partnerships and a proprietary dataset from over 2,000 patients, Acorai aims to transform how heart failure is diagnosed and managed across hospital and remote care settings.

Rubitection is advancing equitable, early-stage detection and care management for chronic wounds, skin-related complications, and autonomic health indicators across all skin tones and care settings. Our solution combines multi-modal sensing including optics and imaging to provide data analytics to support clinicians in identifying and monitoring signs of inflammation, circulatory dysfunction, and skin breakdown that can lead to fatal complications.

We are excited to participate in the 2025 HRX Pitch Competition connect with innovation to leading clinicians, investors, and industry partners to build partnerships that can accelerate commercialization and clinical adoption.  The event also offers valuable peer networking to build relationships. Rubitection is also excited about the opportunity to gain ongoing support and visibility through the HRX Innovation Hub’s yearround community of healthcare innovators.

Kobara Medical is a cardiovascular device company developing Bachmann’s Bundle pacing as the next step in CRT and natural conduction therapy to address one of the largest unmet needs, HFpEF, Heart Failure with Preserved Ejection Fraction.

HRX is focused on cardiovascular innovations and we are excited to showcase our investment opportunity in this space, an electrophysiology solution to Heart Failure, and make new connections with those passionate about addressing heart failure and sharing our vision!

Conform Medical is revolutionizing cardiac arrhythmia treatment with our innovative Atlas 360 catheter, a soft-robotics breakthrough designed to overcome the limitations of current mapping and ablation methods. Our unique “one-size-fits-all” design, featuring inflatable polymer actuators, achieves an unprecedented greater than 90% electrode contact for rapid, whole-chamber mapping of complex arrhythmias like VTach and AFib in seconds, significantly reducing procedure time, cost, and patient risk. This streamlined approach eliminates the need for multiple catheter exchanges and is poised to capture a significant share of the rapidly expanding $10 billion cardiac arrhythmia market. Backed by proven preclinical safety and efficacy data, the Atlas 360 promises to transform electrophysiology practice, ensuring better patient outcomes and enhanced hospital efficiency.

Conform Medical is profoundly excited to be a semifinalist for the HRX Pitch Competition. This unparalleled platform offers direct engagement with leading electrophysiology experts and targeted investors, providing invaluable validation and accelerating our mission to democratize cardiac ablation. We eagerly anticipate showcasing how our innovative catheter will redefine patient care and contribute to the future of heart rhythm management.

Sonaro is a Canadian-based digital health company transforming conventional 2D vascular ultrasound into accessible AI-powered 3D imaging for rapid, reliable stroke risk assessment.

We’re excited to participate in the HRX Pitch Competition to showcase our work and connect with leaders at the intersection of cardiovascular innovation and health technology.

Lumia is the first wearable Continuous Blood Flow Monitor (CBFM). Just as CGMs transformed diabetes care, Lumia’s wearable Continuous Blood Flow Monitoring technology will transform care for people with blood flow issues. Blood flow issues affect a wide range of chronic cardiovascular conditions, from orthostatic conditions (e.g. POTS, Long COVID, Syncope, Orthostatic Hypotension) to fluid management issues (e.g. Heart Failure and Sepsis). By giving patients and providers a real-time window into blood flow to the head, Lumia will improve the diagnosis and management of patients with these issues. Our wearable has been clinically demonstrated at institutions like Johns Hopkins and Duke, and we’re advancing toward FDA clearance for diagnostic use.

Inomagen Therapeutics is a preclinical-stage biotechnology company developing a non-viral gene therapy to improve the treatment of atrial fibrillation.  We have demonstrated  significant preclinical efficacy with our approach, which uses shRNA plasmid(s) to target key molecular mechanisms involved in the genesis of AF.  To achieve targeted gene delivery, we have developed a novel transvenous gene delivery system that uses low energy electroporation to achieve high levels of gene transfection into atrial tissue.

The Pitch Competition provides a tremendous opportunity for Inomagen to share with a distinguished HRX audience of cardiac electrophysiology leaders the progress we are making to bring our novel therapy to clinic with the potential to markedly improve outcomes for the many patients suffering with atrial fibrillation.

Cardiac Innovations, LLC is a digital health company developing pioneering technologies for cardiovascular care. Founded by a team of leading electrophysiologists, biomedical engineers, and experienced MedTech executives, our mission is to simplify and accelerate cardiac device identification to improve patient safety and streamline clinical workflows. Our fully patented SmartRead™ Medical Device Identifier (MDI) instantly identifies the manufacturer of cardiac implantable electronic devices (CIEDs) in less than 10 seconds, a step that traditionally takes clinicians over 30 minutes and often delays care in emergency departments, telemetry units, and imaging centers. Seeing is believing.

SmartRead™ is a universal, handheld platform designed to operate without patient records, rep call-outs, or x-ray confirmation. Its patented signal recognition algorithm enables rapid, noninvasive identification of pacemakers and defibrillators at the point of care, improving safety, optimizing throughput, and reducing cost. The MDI has already received the FDA’s Safe Technologies Program (STeP) designation, and we are exciting about our pending FDA submission. Retrospective studies are underway and we are looking forward to post-market studies. Our vision is to extend SmartRead’s utility across multiple implantable platforms including neurostimulators, gastric devices, orthopedic and other implantable modalities.

We are thrilled to participate in the HRX Pitch Competition because we see it as the ideal venue to amplify the clinical, operational, and patient value of SmartRead™. HRX allows us to connect with fellow digital health innovators and strategic industry leaders to learn from and perhaps help accelerate our roadmap to broader adoption. We’re excited to demonstrate how SmartRead™ enables virtual, sensor-informed carefully aligned with HRX’s mission to transform the future of cardiovascular health.

HRX Pitch Competition semi-finalists will be announced in late summer 2025.

Not for 2025—the application window has closed. But if you have a transformative idea, join us at HRX Live 2025 to prepare for your 2026 pitch!

Yes! All HRX Live 2025 attendees have access to the pitch competition sessions.

Live and in-person on the main stage at HRX Live 2025 in Atlanta, GA, September 4-6, 2025.